Our study revealed that higher percentages of pre- and post-chemoIO CD4+ T cells were independently associated with improved OS and PFS in patients with NSCLC, which was in line with our finding that CD4+/Total T cells ratio before chemoIO therapy was higher in responders than non-responders. This evidence concerns the gene CD4 and non-small cell lung carcinoma.